Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib

被引：1
|
作者：
Walko, C. M.
Aubert, R. E.
La-Beck, N. M.
Hawk, G.
Herrera, V.
Kourlas, H.
Epstein, R. S.
McLeod, H. L.
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA
[2] Medco Hlth Solut Inc, Franklin Lakes, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.9149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9149
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib
    Walko, Christine M.
    Aubert, Ronald E.
    La-Beck, Ninh M.
    Clore, Gosia
    Herrera, Vivian
    Kourlas, Helen
    Epstein, Robert S.
    McLeod, Howard L.
    ONCOLOGIST, 2017, 22 (02): : 208 - 212
  • [2] Subclinical Hypothyroidism in Children and Adolescents: Is It Clinically Relevant?
    Gawlik, Aneta
    Such, Kamila
    Dejner, Aleksandra
    Zachurzok, Agnieszka
    Antosz, Aleksandra
    Malecka-Tendera, Ewa
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [3] Correlation of hypothyroidism with survival in metastatic renal cancer patients treated with sorafenib or sunitinib
    Riesenbeck, L.
    Bierer, S.
    Hoffmeister, I.
    Koepke, T.
    Hertle, L.
    Thielen, B.
    Herrmann, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [4] Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses
    Shu, Mao
    Zai, Xiaoli
    Zhang, Beina
    Wang, Rui
    Lin, Zhihua
    PLOS ONE, 2016, 11 (01):
  • [5] Is Hypothyroidism a Clinically Relevant Toxicity of Tyrosine Kinase Inhibitors?
    Torino, Francesco
    Corsello, Salvatore Maria
    Longo, Raffaele
    Barnabei, Agnese
    Gasparini, Giampietro
    THYROID, 2009, 19 (05) : 539 - 540
  • [6] RACE AND HYPERTENSION - WHAT IS CLINICALLY RELEVANT
    RUTLEDGE, DR
    DRUGS, 1994, 47 (06) : 914 - 932
  • [7] Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
    Riesenbeck, L. M.
    Bierer, S.
    HoVmeister, I.
    Koepke, T.
    Papavassilis, P.
    Hertle, L.
    Thielen, B.
    Herrmann, E.
    WORLD JOURNAL OF UROLOGY, 2011, 29 (06) : 807 - 813
  • [8] Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
    L. M. Riesenbeck
    S. Bierer
    I. Hoffmeister
    T. Köpke
    P. Papavassilis
    L. Hertle
    B. Thielen
    E. Herrmann
    World Journal of Urology, 2011, 29 : 807 - 813
  • [9] Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
    Kristy J. Gotink
    Maria Rovithi
    Richard R. de Haas
    Richard J. Honeywell
    Henk Dekker
    Dennis Poel
    Kaamar Azijli
    Godefridus J. Peters
    Henk J. Broxterman
    Henk M. W. Verheul
    Cellular Oncology, 2015, 38 : 119 - 129
  • [10] Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
    Gotink, Kristy J.
    Rovithi, Maria
    de Haas, Richard R.
    Honeywell, Richard J.
    Dekker, Henk
    Poel, Dennis
    Azijli, Kaamar
    Peters, Godefridus J.
    Broxterman, Henk J.
    Verheul, Henk M. W.
    CELLULAR ONCOLOGY, 2015, 38 (02) : 119 - 129
12345